

# Maroeska te Loo

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/626195/maroeska-te-loo-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36  
papers

947  
citations

17  
h-index

30  
g-index

40  
ext. papers

1,087  
ext. citations

4.1  
avg, IF

3.61  
L-index

#	Paper	IF	Citations
36	Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01. <i>Pediatric Blood and Cancer</i> , <b>2019</b> , 66, e27605	3	14
35	Genetic Variants as Predictive Markers for Ototoxicity and Nephrotoxicity in Patients with Locally Advanced Head and Neck Cancer Treated with Cisplatin-Containing Chemoradiotherapy (The PRONE Study). <i>Cancers</i> , <b>2019</b> , 11,	6.6	8
34	Efficacy and safety of recombinant E. coli asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group. <i>Pediatric Blood and Cancer</i> , <b>2018</b> , 65, e27083	3	10
33	Pediatric Diamond-Blackfan anemia in the Netherlands: An overview of clinical characteristics and underlying molecular defects. <i>European Journal of Haematology</i> , <b>2018</b> , 100, 163-170	3.8	14
32	Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients. <i>Haematologica</i> , <b>2017</b> , 102, 552-561	6.6	10
31	The role of germline variants in chemotherapy outcome in brain tumors: a systematic review of pharmacogenetic studies. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 501-513	2.6	1
30	TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial. <i>BMC Pediatrics</i> , <b>2017</b> , 17, 122	2.6	11
29	Independent development of lymphoid and histiocytic malignancies from a shared early precursor. <i>Leukemia</i> , <b>2016</b> , 30, 955-8	10.7	8
28	Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma. <i>Pharmacogenetics and Genomics</i> , <b>2016</b> , 26, 243-7	1.9	32
27	The role of pharmacogenetics in the treatment of osteosarcoma. <i>Drug Discovery Today</i> , <b>2016</b> , 21, 1775-1886	18.86	47
26	A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3436-41	12.9	29
25	High-quality genotyping data from formalin-fixed, paraffin-embedded tissue on the drug metabolizing enzymes and transporters plus array. <i>Journal of Molecular Diagnostics</i> , <b>2015</b> , 17, 4-9	5.1	9
24	Serum Shiga toxin 2 values in patients during acute phase of diarrhoea-associated haemolytic uraemic syndrome. <i>Acta Paediatrica, International Journal of Paediatrics</i> , <b>2015</b> , 104, e564-8	3.1	15
23	The role of the MTHFR 677C>T polymorphism in methotrexate-induced liver toxicity: a meta-analysis in patients with cancer. <i>Pharmacogenomics Journal</i> , <b>2014</b> , 14, 115-9	3.5	18
22	A germ line mutation in cathepsin B points toward a role in asparaginase pharmacokinetics. <i>Blood</i> , <b>2014</b> , 124, 3027-9	2.2	10
21	A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. <i>Blood</i> , <b>2014</b> , 123, 2026-33	2.2	138
20	Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts. <i>PLoS ONE</i> , <b>2014</b> , 9, e115869	3.7	40

19	The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma. <i>Oncotarget</i> , <b>2014</b> , 5, 12753-68	3.3	37
18	A novel Dutch mutation in UNC13D reveals an essential role of the C2B domain in munc13-4 function. <i>Pediatric Blood and Cancer</i> , <b>2012</b> , 58, 598-605	3	7
17	Survival trends and long-term toxicity in pediatric patients with osteosarcoma. <i>Sarcoma</i> , <b>2012</b> , 2012, 636405	3.1	27
16	Age as prognostic factor in patients with osteosarcoma. <i>Bone</i> , <b>2011</b> , 49, 1173-7	4.7	27
15	Rapid-growing tumor of the cheek mimicking a malignant tumor: lipoblastoma of infancy. <i>Journal of Pediatric Hematology/Oncology</i> , <b>2011</b> , 33, 113-5	1.2	5
14	Taqman genotyping assays can be used on decalcified and paraffin-embedded tissue from patients with osteosarcoma. <i>Pediatric Blood and Cancer</i> , <b>2011</b> , 56, 35-8	3	11
13	Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2011</b> , 66, 1853-6	5.1	45
12	Polymorphisms and mutations of human TMPRSS6 in iron deficiency anemia. <i>Blood Cells, Molecules, and Diseases</i> , <b>2010</b> , 44, 16-21	2.1	44
11	Association of a genetic variant in the ABCC2 gene with high methotrexate plasma concentrations in pediatric malignancies.. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 9522-9522	2.2	3
10	Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes. <i>Nephrology Dialysis Transplantation</i> , <b>2007</b> , 22, 749-55	4.3	29
9	Prognostic significance of blasts in the cerebrospinal fluid without pleiocytosis or a traumatic lumbar puncture in children with acute lymphoblastic leukemia: experience of the Dutch Childhood Oncology Group. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 2332-6	2.2	81
8	Shiga toxin-1 affects nitric oxide production by human glomerular endothelial and mesangial cells. <i>Pediatric Nephrology</i> , <b>2006</b> , 21, 1815-23	3.2	15
7	The effect of flavoring oral rehydration solution on its composition and palatability. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2004</b> , 39, 545-8	2.8	11
6	Decrease of thrombomodulin contributes to the procoagulant state of endothelium in hemolytic uremic syndrome. <i>Pediatric Nephrology</i> , <b>2003</b> , 18, 1066-8	3.2	26
5	Production of hemopexin by TNF-alpha stimulated human mesangial cells. <i>Kidney International</i> , <b>2003</b> , 63, 1681-6	9.9	26
4	Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. <i>Kidney International</i> , <b>2002</b> , 62, 846-56	9.9	94
3	Anticardiolipin antibodies in D+ hemolytic uremic syndrome. <i>Pediatric Nephrology</i> , <b>2002</b> , 17, 1042-6	3.2	4
2	Vero cytotoxin binding to polymorphonuclear leukocytes among households with children with hemolytic uremic syndrome. <i>Journal of Infectious Diseases</i> , <b>2001</b> , 184, 446-50	7	18

- 1 Detection of apoptosis in kidney biopsies of patients with D+ hemolytic uremic syndrome. *Pediatric Research*, **2001**, 49, 413-6 3.2 16